Actinogen Medical Ltd has released a press release.
XanaHES Trial to Continue
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Phase II Alzheimers Disease Trial - results
- March 2019 Quarterly Update
- New Clinical Development Opportunities for Xanamem
- DSMB again reaffirms XanADu trial to continue without change
- 1st participant dosed in important new Xanamem study-XanaHES
Later from Actinogen Medical
- Xanamen Clinical Development & Investor Update
- June 2019 Quarterly Update
- Cognitive improvement demonstrated with Xanamem
- September 2019 Quarterly Update
- R&D Tax Incentive rebate received of $4.58 million
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical